SKB264
Phase 3Small molecule
SKB264 is one of 271 small molecule programs targeting Triple-Negative Breast Cancer. It is currently in Phase 3.
10
Indications
21
Total Trials
20
Active Trials
270
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
706 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1SKB264
SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
Blenoxane
Bristol-Myers SquibbPreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
Spravato
WWim Janssens
Preclinical
Chantix
PPrism Pharmaceuticals
Preclinical
Nubain
AAultman Health Foundation
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Duragesic
CCephalon
Preclinical
Vfend
PPrism Pharmaceuticals
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer5 trials
A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Active, not recruiting·SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.·Phase 3·NCT06448312·406 enrolled
SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.
Recruiting·SSichuan Kelun Pharmaceutical Research Institute Co., Ltd.·Phase 2·NCT05351788·110 enrolled
Show 2 more trials
A Randomized, Open-Label, Multicenter, Phase III Clinical Study of SKB264 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Active, not recruiting·SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.·Phase 3·NCT06670196·420 enrolled
A Randomized, Open-Label, Multicenter Phase 3 Clinical Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Active, not recruiting·SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.·Phase 3·NCT06711900·432 enrolled
Triple-Negative Breast Cancer4 trials
SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer
Active, not recruiting·SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.·Phase 3·NCT05347134·254 enrolled
Show 1 more trial
A Randomized, Open-Label, Multicenter Phase 3 Study of SKB264 Versus Investigator's Choice Chemotherapy as First-Line Treatment in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
Active, not recruiting·SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.·Phase 3·NCT06279364·537 enrolled
Breast Cancer3 trials
NSCLC2 trials
A Multicenter, Single-Arm, Phase II (Simon Two-Stage) Study of Sacituzumab Tirumotecan (SKB264) Plus Glecirasib (KRAS G12C Inhibitor) as First-Line Treatment for KRAS G12C-Mutated Advanced NSCLC
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT07670013·43 enrolled
Selected Subjects With Advanced Solid Tumors1 trial
SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors
Active, not recruiting·SSichuan Kelun Pharmaceutical Research Institute Co., Ltd.·Phase 2·NCT05631262·321 enrolled
6 more indications
Efficacy1 trial
Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC
Not yet recruiting·SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.·Phase 2·NCT07341100·20 enrolled
Phase II1 trial
A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients
Active, not recruiting·SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.·Phase 3·NCT05870319·376 enrolled
Epithelial Ovarian Cancer1 trial
Non-Squamous Non-Small Cell Lung Cancer1 trial
A Phase II Clinical Study to Evaluate Sacituzumab Tirumotecan (SKB264) in Combination With SKB118 for the Treatment of EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer in Participants Who Have Failed Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Therapy
Not yet recruiting·SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.·Phase 2·NCT07854509·110 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SKB264. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details